SOLAEROMED ANNOUNCES COMPLETION OF PHASE IIA PROOF OF CONCEPT RECRUITMENT FOR S-1226TM
CALGARY, Alberta – SolAeroMed Inc., dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases, announced its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology by late Fall 2015. “We are very pleased the clinical trial site has now completed testing of all patients enrolled in the study. With the patient recruitment now complete, all treatment arms of the Trial should be completed by February 2016” said John Dennis, PhD, Chief Executive Officer of SolAeroMed.”